Seres Therapeutics (MCRB) EBT Margin (2016 - 2026)

Seres Therapeutics (MCRB) posted EBT Margin of 7140.78% for Q1 2026, down 65.21% sequentially from 4322.37% in Q4 2025.

Seres Therapeutics (MCRB) EBT Margin (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported EBT Margin for 10 years, with the latest figure at 7140.78% in Q1 2026.

Quarterly EBT Margin changed N/A year-over-year to 7140.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29827.72% (changed N/A YoY) and the FY2025 annual result came in at 51039.92%, changed N/A from the prior year.
EBT Margin retreated to 7140.78% in Q1 2026 per MCRB's latest filing, from 4322.37% in the prior quarter.
Over five years, EBT Margin peaked at 41.52% in Q4 2023 and troughed at 478313.21% in Q3 2022.
A 4-year average of 58695.64% and a median of 7140.78% in 2026 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2023: EBT Margin tumbled 46268038 bps in 2022, then jumped 46334128 bps in 2023.
Over 4 years, EBT Margin stood at 6188.62% in 2022, then soared by 101 bps to 41.52% in 2023, then sank by 10510 bps to 4322.37% in 2025, then tumbled by 65 bps to 7140.78% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 7140.78%, 4322.37%, and 41355.27% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn	35.61%
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn	35.71%
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn	-25.06%
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	12.09%
10	Seres Therapeutics	44.36 Mn	44.36 Mn	-	-2,865.76%

Download Data